$HIMS (-1,55 %) : Online health company Hims and Hers Health missed Wall Street estimates (link) for second-quarter revenue on Monday as it lost subscribers to compounded versions of weight-loss drugs ** Median price target of 14 brokers covering the stock is $48 - LSEG data ** The company's shares fell 12.7% in premarket trading to $55.31
ANALYSTS SEE LONG-TERM GROWTH AS POSITIVE
** Jefferies ("Hold" price target: $51) expects continued volatility in the stock in the near term; adds, "However, we are positive on HIMS' strategies to introduce personalization of healthcare and launch new offerings" ** BTIG ("buy," price target: $85) says the slowdown in commercial GLP-1 subscriptions is likely temporary and expects sequential growth; adds, "GLP-1 volume will shift to shorter duration prescriptions (90 days) and we continue to view the obesity market as robust" ** Canaccord Genuity ("buy", price target: $68) says: "...the introduction of new treatments, continued investment in personalization capabilities, and a growing international presence keep us positive on Hims' long-term growth prospects" ** Leerink Partners ("market perform" price target: $43) says: "HIMS' near-term performance will likely be most dependent on developments in the GLP-1s/weight management space, particularly the pace of international launches in Canada and in conjunction with other international expansion efforts"
Source: reuters.com
